Landsteiner Scientific

Overview

Landsteiner Scientific is a Mexican pharmaceutical company headquartered in Mexico City, dedicated to developing and manufacturing innovative medications for neurodegenerative diseases, cardiovascular disorders, and metabolic conditions. Founded in 2005, Landsteiner Scientific has established itself as a leading Mexican pharmaceutical company focused on bringing novel therapies to the Latin American market.

Overview

Landsteiner Scientific is a Mexican pharmaceutical company headquartered in Mexico City, dedicated to developing and manufacturing innovative medications for neurodegenerative diseases, cardiovascular disorders, and metabolic conditions. Founded in 2005, Landsteiner Scientific has established itself as a leading Mexican pharmaceutical company focused on bringing novel therapies to the Latin American market.

The company's name honors Karl Landsteiner, the Austrian immunologist who discovered blood groups, reflecting its historical roots in hematology and immunology. Today, Landsteiner Scientific operates across multiple therapeutic areas with a focus on diseases prevalent in the Latin American population["landsteiner"].

Company Profile

| Attribute | Value |
|-----------|-------|
| Headquarters | Mexico City, Mexico |
| Founded | 2005 |
| Focus | CNS, cardiovascular, metabolic diseases |
| Employees | ~500 (as of 2024) |
| Stage | Commercial |

Landsteiner Scientific operates from modern manufacturing facilities in the State of Mexico, with distribution networks throughout Mexico and select Latin American countries. The company maintains research collaborations with leading Mexican universities and international partners.

Therapeutic Focus

Neurodegenerative Diseases

Landsteiner Scientific has established programs in Parkinson's disease and related neurodegenerative conditions:

The company recognizes the significant unmet need in Parkinson's treatment in Latin America, where access to novel therapies is limited[schapira2019].

Alzheimer's Disease

Landsteiner offers comprehensive Alzheimer's disease therapies:

• Cholinesterase inhibitors: Donepezil, Rivastigmine, Galantamine
• NMDA antagonist: Memantine
• Combination therapies: Donepezil/Memantine fixed-dose combinations

Cardiovascular Disease

A significant portion of Landsteiner's pipeline focuses on cardiovascular conditions:

Metabolic Disorders

Landsteiner Scientific addresses prevalent metabolic conditions:

Product Portfolio

CNS Products

| Product | Indication | Status |
|---------|------------|--------|
| LST-001 | Parkinson's disease (dopamine agonist) | Approved (Mexico) |
| LST-002 | Parkinson's disease (adjunct therapy) | Phase III |
| LST-003 | Restless legs syndrome | Phase II |
| Donepezil | Alzheimer's disease | Approved |
| Rivastigmine | Alzheimer's disease | Approved |
| Memantine | Alzheimer's disease | Approved |

Cardiovascular Products

| Product | Indication | Status |
|---------|------------|--------|
| LST-CV1 | Hypertension | Approved |
| LST-CV2 | Anticoagulation | Approved |
| LST-CV3 | Hyperlipidemia | Phase III |

Metabolic Products

| Product | Indication | Status |
|---------|------------|--------|
| LST-M1 | Type 2 diabetes | Approved |
| LST-M2 | Obesity | Approved |
| LST-M3 | Metabolic syndrome | Phase II |

Research and Development

Pipeline Strategy

Landsteiner Scientific employs a multi-pronged R&D strategy:

Academic Collaborations

Landsteiner partners with leading Mexican research institutions:

• National Autonomous University of Mexico (UNAM): Basic neuroscience research
• Instituto Politecnico Nacional: Pharmacology and toxicology
• Universidad Nacional Autónoma de México (UNAM): Clinical research
• CINVESTAV: Drug discovery and development

International Partnerships

The company has established licensing agreements with:

• European pharmaceutical companies: Novel compound licensing
• US biotech companies: Technology access agreements
• Japanese pharmaceutical firms: Formulation partnerships

Manufacturing

Landsteiner Scientific operates GMP-certified manufacturing facilities:

• Oral solids: Tablets, capsules, granules
• Injectables: Vials, ampoules
• Topicals: Creams, ointments

Market Position

Landsteiner Scientific is one of the leading Mexican pharmaceutical companies:

| Metric | Position |
|--------|----------|
| CNS market (Mexico) | Top 5 |
| Cardiovascular market (Mexico) | Top 10 |
| Overall pharmaceutical (Mexico) | Top 15 |

The company competes primarily with:

• Pfizer Mexico: Global innovator
• Novartis Mexico: Swiss multinational
• Sanofi Mexico: French pharmaceutical
• Bayer Mexico: German conglomerate
• Generic manufacturers: Local and regional

Regional Expansion

Landsteiner Scientific has expanded beyond Mexico:

The company tailors products to regional disease burden and regulatory requirements.

Regulatory Affairs

Landsteiner maintains regulatory expertise across Latin America:

• Mexico: COFEPRIS registration and compliance
• Central America: REGUMAT regulatory harmonization
• Colombia: INVIMA registration
• Brazil: ANVISA consultation (planned)

Corporate Social Responsibility

Landsteiner Scientific is committed to improving healthcare access:

Financial Performance

Landsteiner Scientific has shown steady growth:

| Metric | 2023 | 2022 |
|--------|------|------|
| Revenue | $85M | $78M |
| R&D | $12M | $10M |
| Employees | 500 | 480 |

Revenue is generated through product sales in Mexico and regional exports.

Future Directions

Landsteiner Scientific's strategic priorities include:

See Also

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Mexican Pharmaceutical Companies](/companies/mexican-pharma-overview)
• [Cardiovascular Disease Treatments](/diseases/cardiovascular-overview)
• [Latin America Biotech](/companies/latam-biotech-overview)

References